Imipenem + cilastatin (combination preparation)
Generic name
Imipenem + cilastatin (combination preparation)
Brand name
ATC Code
J01DH51
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Mean clearance (CL) and volume of distribution (Vdss) of imipenem were approximately 45% higher in pediatric patients (3 months to 14 years) than in adults. [SmPC]
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Bacterial infections |
|---|
|
| Infection in cystic fibrosis |
|---|
|
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Dose adjustment not neededGFR 30-50 ml/min/1.73 m2
Dose adjustment not neededGFR 10-30 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 12 uurGFR < 10 ml/min/1.73 m2
A general recommendation is not providedThe complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Imipenem / cilastatin accumulates in patients with renal impairment. If the dose is not adjusted to kidney function, side effects to the central nervous system may occur. Special attention should be paid to neurological symptoms or convulsions in children with known risk factors for seizures, or who use concomitant drugs that lower the seizure threshold.
Use is not recommended for CNS infections. [Ref.]
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
OTHER BETA-LACTAM ANTIBACTERIALS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| First-generation cephalosporins | ||
|---|---|---|
| J01DB05 | ||
| J01DB04 | ||
| J01DB01 | ||
| J01DB03 | ||
| Second-generation cephalosporins | ||
|---|---|---|
| J01DC04 | ||
| J01DC03 | ||
| J01DC02 | ||
| Third-generation cephalosporins | ||
|---|---|---|
| J01DD08 | ||
| J01DD01 | ||
| J01DD13 | ||
| J01DD52 | ||
| J01DD02 | ||
| J01DD14 | ||
| J01DD04 | ||
| Fourth-generation cephalosporins | ||
|---|---|---|
| J01DE01 | ||
| Monobactams | ||
|---|---|---|
| J01DF01 | ||
| Carbapenems | ||
|---|---|---|
| J01DH03 | ||
| J01DH02 | ||
| MONOBACTAMS | ||
|---|---|---|
| J01DF01 | ||
| Other cephalosporins and penems | ||
|---|---|---|
| J01DI02 | ||
References
- Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
- Merck Sharp & Dohme B.V., SPC Tienam (RVG 11089) 19-11-2020, www.geneesmiddeleninformatiebank.nl
- AVOXA ABDA-Datenbank, Interaktionen Impinemen_Cilastatin, accessed 07-2018
- MSD SHARP & DOHME GMBH, SmPC Zienam 500mg/500mg Pulver zur Herstellung einer Infusionslösung (4697.01.00), 11/2015
- Fresenius Kabi, SmPC Imipenem/Cilastatin 500mg/500mg Pulver zur Herstellung einer Infusionslösung (71957.00.00), 08/2012
- UpToDate® Pediatric Drug information, Imipenem/Cilastatin Lexicomp® Version 132.0, accessed 07/2018
- AVOXA ABDA-Datenbank, Interaktionen Impinemen_Cilastatin, accessed 07-2018
Changes
Therapeutic Drug Monitoring
Overdose
